Stratification

Stratification

  1. lut 28, 2025

What Does the 'Stratification’ Mean?

Stratification in clinical research refers to the process of dividing study participants into subgroups based on specific characteristics or factors. These factors can include age, gender, disease severity, or other relevant variables that might influence the study outcomes.

The primary purpose of stratification is to ensure a balanced distribution of important variables across treatment groups. By doing so, researchers can minimize bias, increase statistical power, and improve the validity of their results when comparing different interventions or treatments.

Why Is the 'Stratification’ Important in Clinical Research?

Stratification is crucial in clinical research as it helps control for confounding variables that could skew study results. By ensuring a balanced distribution of key characteristics across treatment groups, researchers can more accurately attribute observed effects to the intervention being studied rather than to pre-existing differences between groups.

Furthermore, stratification enhances the statistical power and efficiency of clinical trials. It allows for more precise subgroup analyses, which can reveal important differences in treatment effects among specific patient populations, ultimately leading to more personalized and effective medical interventions.

Good Practices and Procedures

  1. Identify stratification factors early in the study design phase, preferably during protocol development
  2. Limit the number of stratification factors to avoid overly complex randomization and small subgroups
  3. Use dynamic allocation methods, such as minimization, for studies with multiple stratification factors
  4. Implement stratification through a validated computerized system to ensure accuracy and reduce human error
  5. Document the stratification process thoroughly in the statistical analysis plan for transparency and reproducibility

Related Terms

Read more

Axcellant partners with Prometheus MedTech.AI to accelerate AI-powered cardiac diagnostics

We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…

Axcellant at EANM 2025: What We Brought Back from Barcelona

The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…

Radioisotopes in Medicine: Clinical Applications, Safety, and Regulatory Considerations

The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…